GRAIL’s Galleri test wins endorsement from FDA panel (NASDAQ:GRAL)

A panel of US FDA advisors voted that there is reasonable evidence that GRAIL’s (GRAL) multi-cancer early detection blood test Galleri is effective. The vote was 6-4.

Members of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory